Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 44,192 |
|
|||||
| News | - | ||||||
| Day High | 37.20 | Low High |
|||||
| Day Low | 35.69 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Neurogene Inc | NGNE | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.24 | 3.50% | 36.63 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 36.02 | 35.69 | 37.20 | 36.63 | 35.39 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,766 | 44,192 | US$ 36.67 | US$ 1,620,571 | - | 12.49 - 53.00 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:20:20 | 1 | US$ 36.09 | USD |
Neurogene Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 32.8M | 9.40M | - | 0 | -36.32M | -3.86 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Neurogene News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/22/2024 | 15:36 | Business Wire | Neurogene Announces Upcoming Presentation of Safety Data.. |
| 3/18/2024 | 15:14 | Business Wire | Neurogene Reports Fourth Quarter and Full Year 2023.. |
| 3/04/2024 | 06:30 | Business Wire | Neurogene Announces Expansion and Plans for More Rapid.. |
| 2/29/2024 | 06:30 | Business Wire | Neurogene to Participate in Upcoming Investor Conferences |
| 1/16/2024 | 06:00 | Business Wire | Neurogene Announces Appointment of Julie Jordan, M.D., as.. |
| 1/05/2024 | 06:00 | Business Wire | Neurogene Announces Business Update and 2024 Outlook |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NGNE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 29.89 | 37.20 | 29.88 | 33.79 | 92,880 | 6.74 | 22.55% |
| 1 Month | 43.06 | 43.66 | 28.09 | 35.42 | 93,337 | -6.43 | -14.93% |
| 3 Months | 29.55 | 53.00 | 28.09 | 39.45 | 143,256 | 7.08 | 23.96% |
| 6 Months | 14.57 | 53.00 | 12.49 | 36.06 | 122,032 | 22.06 | 151.41% |
| 1 Year | 14.57 | 53.00 | 12.49 | 36.06 | 122,032 | 22.06 | 151.41% |
| 3 Years | 14.57 | 53.00 | 12.49 | 36.06 | 122,032 | 22.06 | 151.41% |
| 5 Years | 14.57 | 53.00 | 12.49 | 36.06 | 122,032 | 22.06 | 151.41% |
Neurogene Description
| Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. |
